ADMA Biologics (ADMA) Misses Q3 EPS by 9c

ADMA Biologics (NASDAQ: ADMA) reported Q3 EPS of ($0.48), $0.09 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $1.85 million versus the consensus estimate of $1.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
• ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline